Loading...
•
Mar 31, 2021
Zimmer Biomet Q1 2021 Earnings Report
Zimmer Biomet's first quarter results exceeded expectations with net sales increasing and adjusted diluted earnings per share rising slightly year-over-year.
Key Takeaways
Zimmer Biomet reported a stronger than anticipated first quarter, driven by signs of the pandemic subsiding in many regions due to accelerated vaccine rollouts. Net sales increased by 3.6% to $1.847 billion, and adjusted diluted earnings per share increased by 0.6% to $1.71.
First quarter net sales increased by 3.6% to $1.847 billion, or 0.8% on a constant currency basis.
Diluted earnings per share were $0.94, while adjusted diluted earnings per share were $1.71.
The company provided full-year 2021 guidance, expecting 14% to 17% revenue growth on a reported basis and 12.5% to 15.5% on a constant currency basis versus 2020.
Zimmer Biomet continues to transform its business and drive significant value for stakeholders.
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Zimmer Biomet Revenue by Geographic Location
Revenue by Segment
Knees Revenue
CapyFin.comHips Revenue
CapyFin.comS.E.T. Revenue
CapyFin.comTech/Data/Surgical Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Zimmer Biomet provided full-year 2021 financial guidance, expecting 14% - 17% reported revenue growth.
Positive Outlook
- Projected Year Ending December 31, 2021 2021 reported revenue growth 14% - 17%
- Foreign Currency Exchange Impact 1.5%
- Adjusted Operating Profit Margin(1) 26.5% - 27.5%
- Adjusted Tax Rate(1) 16.0% - 16.5%
- Adjusted Diluted EPS(1) $7.60 - $8.00
Revenue & Expenses
Visualization of income flow from segment revenue to net income